NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However ...

Walmart's Flipkart has secured a lending licence from the Indian central bank and banking regulator, enabling it to offer ...

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

With a market cap of around $136 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company. The Foster City, ...